The present invention generally relates to the polymorph Form 2 of [3-(4-methoxy-2-methyl-phenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin-7-yl]-[(S)-1-(3-methyl-[1,2,4]oxa-diazol-5-yl)-propyl]amine. The present invention also relates to pharmaceutical compositions comprising the same and methods of using the same.